BioSpace News Archive

Coherus BioSciences, Inc., announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston.

Aulos Bioscienc presented new pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007, the first human monoclonal antibody designed using artificial intelligence to be tested in a clinical trial.

Prelude Therapeutics Incorporated announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density.

Cogent Biosciences, Inc. announced updated preclinical data from the Company’s next-generation selective fibroblast growth factor receptor 2 program being presented in a poster presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston.

Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death.

Verastem Oncology announced the initial safety, pharmacokinetics and recommended Phase 2 dose in the RAMP 203 trial evaluating the safety, tolerability and efficacy of avutometinib in combination with sotorasib in patients with KRAS G12C-mutant non-small cell lung cancer.

Ankyra Therapeutics presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.

Avistone Biotechnology Co., Ltd announced results from its China and US IND enabling nonclinical studies for ANS014004, a novel small-molecule type II c-Met tyrosine kinase inhibitor.

Sihuan Pharmaceutical Holdings Group Ltd. is pleased to announce that the “Group” was selected as one of the first echelon of enterprises in The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023.